Novan

Novan, Inc. is a biotechnology company, which engages in leveraging nitric oxide’s natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-mediated diseases. Its products pipeline includes SB204, SB206, SB208, and SB414. The company was founded by Mark Schoenfisch and Nathan Stasko in 2006 and is headquartered in Durham, NC.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novan develops products that tap the anti-bacterial properties of nitric oxide by encapsulating the compound in nano-particles that deliver therapeutic agents to desired body location. They use its proprietary nitric oxide-based science and technology platform to develop innovative, first-in-class therapies for unmet medical needs. The company is committed to using the power of the human body to create safe and effective treatments. They complement their internal scientific talent with strategic partners around the globe to enable Novan to harness the power of nitric oxide and develop technologies that will help address currently untreated and under-treated medical conditions. It was incorporated in 2008 and is based in Morrisville, North Carolina.

DURHAM, N.C., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its third quarter 2022 financial results on Monday, November 14th. Novan management will host a conference call and live audio webcast to discuss the operational and financial results at 8:30 a.m. ET that same day.

Novan to Report Third Quarter 2022 Financial Results on November 14, 2022

Data collected shows importance of treatment formulation characteristics and speed of improvement in psoriasis symptoms to patient treatment adherence Data collected shows importance of treatment formulation characteristics and speed of improvement in psoriasis symptoms to patient treatment adherence

EPI Health, a Novan Company, and MC2 Therapeutics Announce Data from Survey Conducted by National Psoriasis Foundation Presented at 42nd Annual Fall Clinical Dermatology Conference®

Research shows PAD (Polyaphron Dispersion) Technology™ leads to more efficient delivery of Calcipotriene (CAL) and Betamethasone Dipropionate (BDP) than CAL/BDP topical suspension Research shows PAD (Polyaphron Dispersion) Technology™ leads to more efficient delivery of Calcipotriene (CAL) and Betamethasone Dipropionate (BDP) than CAL/BDP topical suspension

EPI Health, a Novan Company, and MC2 Therapeutics Present New Data In Multiple Posters Highlighting WYNZORA's® Unique PAD Technology™ at the 42nd Annual Fall Clinical Dermatology Conference®

DURHAM, N.C., Oct. 14, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN) and EPI Health, a Novan Company, today announced that eight abstracts have been accepted for poster presentation at the 42nd Annual Fall Clinical Dermatology Conference® being held October 20-23, 2022, in Las Vegas, NV.

Novan and EPI Health, a Novan Company, Announce Abstracts Accepted for Poster Presentation at the 42nd Annual Fall Clinical Dermatology Conference®

– New data analysis from previously completed successful Phase 3 study1 demonstrated WYNZORA® Cream to be effective and convenient for skin of color patients for the treatment of plaque psoriasis

EPI Health, a Novan Company, and MC2 Therapeutics Present WYNZORA® (calcipotriene and betamethasone dipropionate) Cream, 0.005%/0.064% Subgroup Data Analysis at Skin of Color Update 2022 Conference

Novan, Inc. (NASDAQ:NOVN ) Q2 2022 Earnings Conference Call August 11, 2022 8:30 AM ET Company Participants Paula Stafford - President, CEO & Chairwoman John Gay - CFO & Corporate Secretary John Donofrio - EVP, COO & President, EPI Health Conference Call Participants Jeff Jones - Oppenheimer Brian Dolliver - Brookline Capital Markets Jonathan Aschoff - ROTH Capital Partners Oren Livnat - H.C. Wainwright & Co. John Vandermosten - Zacks Small-Cap Research Jennifer Kim - Cantor Fitzgerald & Co. Operator Hello, and welcome to the Novan, Inc. Quarterly Update Conference Call and Webcast.

Novan, Inc. (NOVN) CEO Paula Stafford on Q2 2022 Results - Earnings Call Transcript

– Total revenue of $6.2 million for the second quarter 2022 –

Novan Reports Second Quarter 2022 Financial Results and Provides Corporate Update

DURHAM, N.C., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its second quarter 2022 financial results on Thursday, August 11th. Novan management will host a conference call and live audio webcast to discuss the operational and financial results at 8:30 a.m. ET that same day.

Novan to Report Second Quarter 2022 Financial Results on August 11, 2022

– Novan and Evening Post Group enter into a loan payoff and termination agreement, fully satisfying the promissory note and all related obligations –

Novan Satisfies $16.5 Million Outstanding Promissory Note

DURHAM, N.C., June 13, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced the closing of the Company's previously announced registered direct offering priced at-the-market under Nasdaq rules with an institutional investor of an aggregate of (i) 2,080,696 shares of its common stock and accompanying warrants to purchase up to 2,080,696 shares of common stock and (ii) pre-funded warrants to purchase up to 3,180,615 shares of common stock and accompanying warrants to purchase up to 3,180,615 shares of common stock, resulting in total gross proceeds of approximately $15.0 million.

Novan Announces Closing of Approximately $15.0 Million Registered Direct Offering Priced At-the-Market

DURHAM, N.C., June 09, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced it has entered into a definitive agreement with an institutional investor to sell to the investor, in a registered direct offering priced at-the-market under Nasdaq rules, (i) 2,080,696 shares of its common stock and accompanying warrants to purchase up to 2,080,696 shares of common stock and (ii) pre-funded warrants to purchase up to 3,180,615 shares of common stock and accompanying warrants to purchase up to 3,180,615 shares of common stock, for aggregate gross proceeds of approximately $15.0 million.

Novan Announces Approximately $15.0 Million Registered Direct Offering Priced At-the-Market

– Based on clinical data from previously completed B-SIMPLE4 pivotal Phase 3 clinical study, berdazimer gel, 10.3% (SB206) can shorten the duration of molluscum infection and increase the chance of clearance by enhancing inflammation of molluscum –

Novan to Present Berdazimer Gel, 10.3% (SB206) Clinical Data at Annual Meeting of the Society for Investigative Dermatology

Novan, Inc. (NASDAQ:NOVN ) Q1 2022 Earnings Conference Call May 16, 2022 8:30 AM ET Company Participants Paula Brown Stafford - Chairman, President and Chief Executive Officer John Donofrio - Chief Operating Officer, Novan and President, EPI Health John Gay - Chief Financial Officer Conference Call Participants Jennifer Kim - Cantor Fitzgerald Kemp Dolliver - Brookline Capital John Vandermosten - Zacks Jonathan Aschoff - Roth Capital Partners Operator Hello and welcome to the Novan, Incorporated Quarterly Update Conference Call and Webcast. As a brief reminder, all participants are currently in a listen-only mode.

Novan, Inc. (NOVN) CEO Paula Brown Stafford on Q1 2022 Results - Earnings Call Transcript

– Transformational quarter for Novan, marked by acquisition of EPI Health –

Novan Reports First Quarter 2022 Financial Results and Provides Corporate Update

DURHAM, N.C., May 06, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its first quarter 2022 financial results on Monday, May 16th. Novan management will host a conference call and live audio webcast to discuss the operational and financial results at 8:30 a.m. ET that same day.

Novan to Report First Quarter 2022 Financial Results on May 16, 2022

Live moderated video webcast with members of the Novan management team on Tuesday, April 26th at 2:00 PM ET Live moderated video webcast with members of the Novan management team on Tuesday, April 26th at 2:00 PM ET

Novan to Participate in the Virtual Investor Innovation in Dermatology Spotlight Event

DURHAM, N.C., March 24, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that data from its pivotal Phase 3 study of berdazimer gel 10.3% (SB206) for the treatment of molluscum contagiosum was selected for an oral presentation at a late-breaker session at the American Academy of Dermatology's (AAD) 2022 Annual Meeting.

Novan Announces Late-Breaking Abstract Accepted for Presentation at American Academy of Dermatology's (AAD) 2022 Annual Meeting

DURHAM, N.C., March 14, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that Paula Brown Stafford, President and Chief Executive Officer of Novan, will be presenting at two upcoming investor conferences.

Novan, Inc. to Present at Two Upcoming Investor Conferences

CHARLESTON, S.C., March 11, 2022 /PRNewswire/ -- Evening Post Group ("EPG"), a family-owned operating group based in Charleston, South Carolina, is excited to announce the successful sale of EPI Health, LLC to Novan, Inc (NASDAQ: NOVN), a public specialty dermatology company based out of Durham, North Carolina.

EVENING POST GROUP SELLS EPI HEALTH TO NOVAN, INC

Novan Inc (NASDAQ: NOVN) has acquired EPI Health LLC, a specialty pharmaceutical company focused on the U.S. dermatology market.  EPI Health offers a product portfolio that includes four prescription products across psoriasis, rosacea, dermatosis, and acne, with a 2021 operating.

Novan Acquires EPI Health To Bolster Commercial Force For Potential Marketing Of Its lead Products

Acquisition Represents Forward Integration as a Commercial Organization Acquisition Represents Forward Integration as a Commercial Organization

Novan Acquires EPI Health, a Specialty Dermatology Company

Novan, Inc. (NOVN) CEO Paula Brown Stafford on Q4 2021 Results - Earnings Call Transcript

– First New Drug Application (NDA) submission targeted in Q4 2022 for lead program SB206 (berdazimer gel 10.3%) for molluscum contagiosum –

Novan Reports Full Year 2021 Financial Results and Provides Corporate Update

DURHAM, N.C., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its full year 2021 financial results on Tuesday, February 22nd. Novan management will host a conference call and live audio webcast to discuss the operational and financial results at 8:30 a.m. ET that same day.

Novan to Report Full Year 2021 Financial Results on February 22, 2022

DURHAM, N.C., Jan. 14, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that data from the Company's completed Phase 2 and Phase 3 clinical studies of berdazimer 10.3% gel (previously referred to as SB206) for molluscum contagiosum will be presented at the 2022 Winter Clinical Dermatology Conference, being held January 14-19, 2022, in Koloa, Hawaii.

News for Novan Stock (NOVN)